Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) SEC filings page on Stock Titan provides structured access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, Catalyst uses its filings to report on financial performance, material events, capital allocation decisions, and developments affecting its product portfolio, including FIRDAPSE, AGAMREE, and FYCOMPA.
Investors can review current reports on Form 8-K, where Catalyst discloses events such as quarterly financial results, authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, changes to clinical practice guidelines referencing Lambert-Eaton myasthenic syndrome and amifampridine, and updates to its Board of Directors. These filings often incorporate press releases as exhibits, providing additional context on how specific events may influence the company’s operations and CPRX stock.
In addition to event-driven 8-Ks, users can access periodic reports like Forms 10-Q and 10-K, which contain detailed discussions of product revenue, research and development spending, selling and administrative costs, and other aspects of Catalyst’s business. For a biopharmaceutical issuer, these reports are key resources for understanding revenue contributions from individual products, the status of rare disease programs, and the company’s approach to intellectual property and litigation.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify items such as revenue trends, material agreements, or litigation outcomes. The platform also surfaces insider transaction reports on Form 4 when available, giving additional visibility into trading activity by officers and directors. With real-time updates from EDGAR and simplified explanations of complex regulatory documents, this CPRX filings page supports efficient, in-depth analysis of Catalyst Pharmaceuticals’ regulatory record.
Catalyst Pharmaceuticals Inc Schedule 13G/A amendment shows The Vanguard Group reports zero beneficial ownership of Common Stock as of the filing, with 0 shares and 0% of the class. The amendment notes an internal realignment at Vanguard and that certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
Catalyst Pharmaceuticals, Inc. filed an amended current report to correct a scrivener’s error in the signature date of a previously submitted report. No other changes were made.
The company also notes that a federal court in New Jersey has delayed the start of a bench trial with Hetero USA, Inc. concerning the validity of its Orange Book-listed FIRDAPSE® patents, which expire in 2032, 2034, and 2037, moving the trial start from March 23, 2026 to May 18, 2026.
Catalyst Pharmaceuticals, Inc. reports that a federal court has postponed the start of its pending patent bench trial against Hetero USA, Inc. The District Court for the District of New Jersey rescheduled the trial from March 23, 2026 to May 18, 2026.
The case concerns the validity of Catalyst’s Orange Book-listed patents covering FIRDAPSE, which currently expire in 2032, 2034, and 2037. The filing does not change the claims themselves, but indicates the timetable for resolving this patent dispute has been extended by nearly two months.
Catalyst Pharmaceuticals reported record 2025 results, with total revenues of $589.0 million, up 19.8% year over year, and GAAP net income of $214.3 million. Growth was led by FIRDAPSE product revenue of $358.4 million, up 17.1%, and AGAMREE revenue of $117.1 million, up 154.3%, while FYCOMPA revenue declined 17.4% to $113.3 million as generics entered the market.
Cash and cash equivalents rose to $709.2 million as of December 31, 2025, helped by strong profitability, partially offset by $25.3 million of share repurchases. For 2026, the company guides total revenues to $615–$645 million, with higher expected sales from both FIRDAPSE and AGAMREE and a sharply lower FIRDAPSE U.S. royalty burden, as the overall upstream rate drops to 6% beginning January 26, 2026.
Catalyst Pharmaceuticals describes a commercial-stage rare disease business built around three neurology products: FIRDAPSE for Lambert‑Eaton myasthenic syndrome (LEMS), AGAMREE for Duchenne muscular dystrophy (DMD), and FYCOMPA for epilepsy. The company emphasizes patient-support infrastructure through its Catalyst Pathways program and extensive field, medical, and reimbursement teams.
Catalyst reports approximately $709.2 million in cash and cash equivalents as of December 31, 2025 and believes this supports operations for at least the next 12 months. A share repurchase program authorizes up to $200 million of buybacks through December 31, 2026; by February 23, 2026, it had repurchased 1,740,713 shares for about $39.9 million.
The filing details settlements with several generic challengers to FIRDAPSE and ongoing Paragraph IV litigation with Hetero covering patents expiring between 2032 and 2037, alongside upcoming loss of orphan exclusivity in November 2025. For AGAMREE, Catalyst outlines a North American license with Santhera, including a $75 million upfront payment, a $36 million FDA‑approval milestone, and additional sales‑based milestones after 2025 net product revenue exceeded $100 million. FYCOMPA’s main patents expire by July 1, 2026, and multiple generics are already on the market, leading Catalyst to cease active marketing after December 31, 2025 while continuing to sell both tablets and oral suspension.
Catalyst Pharmaceuticals Chief HR Officer Gregg Russo reported equity compensation activity. On February 17, 2026, 687 restricted stock units vested and converted into an equal number of common shares at $0.00 per share. Of these, 211 shares were withheld to cover taxes, leaving 476 shares delivered. The derivative award vests in five equal annual tranches each February 13 from 2026 through 2030, with shares required to be delivered within sixty days of vesting.
Catalyst Pharmaceuticals, Inc. reported that it will present at the 44th Annual JP Morgan Healthcare Conference on January 12, 2026. The company has made its conference slide presentation available as Exhibit 99.1 to this report and incorporates it by reference. The disclosure is furnished under Regulation FD, meaning it is not treated as filed for liability purposes or automatically included in other securities law filings. The company also highlights that the report and presentation contain forward-looking statements and directs readers to its Form 10-K for the year ended December 31, 2024 and subsequent SEC reports for a discussion of risks that could cause actual results to differ.
Catalyst Pharmaceuticals President and CEO Richard J. Daly reported equity compensation activity. On January 5, 2026, 42,105 restricted stock units vested and were converted into an equal number of Catalyst common shares at a price of $0 per share. According to the filing, this award vests in five equal annual tranches from January 1, 2025 through January 1, 2029.
To cover withholding taxes tied to the vesting, the company withheld 10,577 common shares, leaving Daly with 271,266 common shares directly owned after the transactions. He also reported 2,618,539 restricted stock units beneficially owned following this vesting event.
Catalyst Pharmaceuticals director Molly Harper reported exercising stock options and selling common shares of the company. On 12/12/2025, she exercised options to purchase 20,000 shares of common stock at an exercise price of $5.78 per share, converting them into common shares. She then sold common stock in several open-market transactions, including 15,527 shares at a weighted average price of $23.198, 4,473 shares at $23.734, and 6,746 shares at $23.06 per share. Following these transactions, she directly beneficially owned 2,360 shares of common stock and 128,497 options to purchase common stock. The sales were made on the open market for personal reasons and to help fund the option exercise, and were not due to any disagreement with the company.
Catalyst Pharmaceuticals, Inc. (CPRX) chairman of the board and director Patrick J. McEnany reported stock gifts to family trusts. On 12/01/2025, he made bona-fide gifts of common stock, par value $0.001 per share, recorded at a price of $0 per share, classified under transaction code "G" for gifts. After the reported transactions, he directly beneficially owned 4,148,477 shares of Catalyst Pharmaceuticals common stock. The explanation notes that the gifts were to irrevocable trusts for family members who do not share his household, and he is not a trustee and has no direct or indirect influence over the trusts' investment decisions.